EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expression Modulation of Immune Inhibitory Molecules by Small Molecule Inhibitor Drugs in Leukemic Cells of Chronic Lymphocytic Leukemia

Fatemeh Mousavi-Mirkalaei iD, Saeid Taghiloo iD, Maryam Alizadeh-Foroutan iD, Ehsan Zaboli iD, Mohammad Eslami-Jouybari iD, Ramin Shekarriz iD, Leila Mirzakhani iD, Zohreh Ehsani iD, Sahar Khosravi iD, Fatemeh Karimpour iD, Hossein Asgarian-Omran iD

Iranian Journal of Pharmaceutical Research · 12.08.2025 · 24 (1)

DOI: 10.5812/ijpr-159353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 12.08.2025. Verfasst von Fatemeh Mousavi-Mirkalaei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Targeted therapy with small molecule inhibitors (SMIs) has been considered a highly effective therapeutic strategy for chronic lymphocytic leukemia (CLL). However, there is little information on the detailed mechanisms and association of SMIs with immune evasion mechanisms.

Objectives

This study examined the effects of signaling pathway inhibitors ibrutinib, idelalisib, duvelisib, and venetoclax on the expression of immune checkpoint ligands: Programmed death ligand 1 (PD-L1), galectin-9 (Gal-9), cluster of differentiation (CD)200, CD155, and herpes virus entry mediator (HVEM) in CLL leukemic cells.

Methods

Leukemic cells were isolated from fifteen CLL patients using the magnetic activated cell sorting method, confirmed by flow cytometry, and then cultured and treated with different SMIs for 72 hours. The optimal doses of the applied SMIs for in-vitro treatment were determined by MTT assay. The mRNA expression was measured by real-time PCR assay using β-actin as a housekeeping gene.

Results

The purity of isolated CLL leukemic cells was determined to be more than 97%, as confirmed by dual-color flow cytometry. Based on the IC50 results obtained from the MTT assay, the optimal doses of 5, 15.03, 1.07 μM, and 0.5 nM were determined for ibrutinib, idelalisib, duvelisib, and venetoclax, respectively. None of the SMI drugs showed changes in PD-L1 expression levels compared to the untreated group. Additionally, the level of Gal-9 mRNA expression was slightly decreased in all treated groups. The expression level of CD155 was downregulated only after treatment with venetoclax, and an upregulation was observed in the other treated groups. Finally, ibrutinib and idelalisib indicated a mild non-significant upregulation in HVEM gene expression.

Conclusions

Altogether, the treatment of leukemic cells with different SMIs in this study indicated increased or decreased variations in the expression level of immune checkpoint inhibitory ligands in CLL. Therefore, these mechanisms should be considered for further treatment approaches, especially for combinational strategies.

Schlagwörter

Stichwörter der Autor:innen

CD155CD200Chronic Lymphocytic LeukemiaGal-9HVEMPDL-1Small Molecule Inhibitors

Autor:innen und Institutionen

  • Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Gastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
  • Department of Hematology and Oncology, Imam Khomeini Hospital, Mazandaran University of Medical Science, Sari, Iran.
  • Cancer Research Center, Health Research Institute, Babol University of Medical Science, Babol, Iran.

ORCID-Profile: Fatemeh Mousavi-Mirkalaei, Saeid Taghiloo, Maryam Alizadeh-Foroutan, Ehsan Zaboli, Mohammad Eslami-Jouybari, Ramin Shekarriz, Leila Mirzakhani, Zohreh Ehsani, Sahar Khosravi, Fatemeh Karimpour, Hossein Asgarian-Omran

Zitieren

APA

Mousavi-Mirkalaei, F., Taghiloo, S., Alizadeh-Foroutan, M., Zaboli, E., Eslami-Jouybari, M., Shekarriz, R., Mirzakhani, L., Ehsani, Z., Khosravi, S., Karimpour, F., & Asgarian-Omran, H. (2025). Expression Modulation of Immune Inhibitory Molecules by Small Molecule Inhibitor Drugs in Leukemic Cells of Chronic Lymphocytic Leukemia. Iranian Journal of Pharmaceutical Research, 24(1). https://doi.org/10.5812/ijpr-159353

Vancouver

Mousavi-Mirkalaei F, Taghiloo S, Alizadeh-Foroutan M, Zaboli E, Eslami-Jouybari M, Shekarriz R, et al. Expression Modulation of Immune Inhibitory Molecules by Small Molecule Inhibitor Drugs in Leukemic Cells of Chronic Lymphocytic Leukemia. Iranian Journal of Pharmaceutical Research. 2025;24(1). doi:10.5812/ijpr-159353

BibTeX
@article{MousaviMirkalaei2025,
  author = {Mousavi-Mirkalaei, Fatemeh and Taghiloo, Saeid and Alizadeh-Foroutan, Maryam and Zaboli, Ehsan and Eslami-Jouybari, Mohammad and Shekarriz, Ramin and Mirzakhani, Leila and Ehsani, Zohreh and Khosravi, Sahar and Karimpour, Fatemeh and Asgarian-Omran, Hossein},
  title = {Expression Modulation of Immune Inhibitory Molecules by Small Molecule Inhibitor Drugs in Leukemic Cells of Chronic Lymphocytic Leukemia},
  journal = {Iranian Journal of Pharmaceutical Research},
  year = {2025},
  volume = {24},
  number = {1},
  doi = {10.5812/ijpr-159353}
}
Kostenlos starten →